Navigation Links
Pharmacyclics Reports Third Quarter 2013 Results
Date:11/7/2013

iffuse large B-cell lymphoma (DLBCL). This multicenter, open-label trial designed to assess the activity of ibrutinib in two genetically distinct subtypes of DLBCL, the activated B-cell (ABC) subtype and the germinal center B-cell (GCB) subtype started in the second quarter of 2011. This trial is active in several US sites and Pharmacyclics has enrolled 70 patients with updated results most recently published at the Annual Meeting of the European Hematology Association in June of 2013. In July of 2013 a new cohort with ibrutinib dosed at 840mg in patients with non-GCB subtype DLBCL was initiated. Pharmacyclics is currently enrolling patients in this new cohort.
  • DBL1002: Phase Ib dose escalating study of ibrutinib in combination with R-CHOP in patients with newly diagnosed CD20 positive B-cell Non Hodgkin Lymphoma (DLBCL, MCL, FL) started in the second quarter of 2012. The purpose of this study is to identify a safe and tolerable dose of ibrutinib in combination with R-CHOP. This global, multi-center study has been fully accrued with 17 patients and an update on the dose escalating phase of this study was provided at ASCO 2013. With a recommended Phase II dose established, an additional 15 patients with newly diagnosed DLBCL enrolled in the study. DBL1002 is currently in the follow up phase.
  • DBL3001: Phase III study of ibrutinib in combination with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with newly diagnosed the non-GCB subtype of DLBCL started in the third quarter of 2013. This is a randomized, multi-center, double-blinded, controlled trial of ibrutinib plus R-CHOP versus R-CHOP in patients with newly diagnosed non-GCB subtype DLBCL. The primary endpoint of the study is to demonstrate a clinically significant improvement in event-free survival when compared to R-CHOP. The enrollment target of this global study is 800 patients.
  • FL

  • FLR2002: Phase II study of ibrutinib in pat
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

    Related medicine technology :

    1. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
    2. Pharmacyclics Reports Second Quarter 2013 Results
    3. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
    4. Pharmacyclics Reports First Quarter 2013 Results
    5. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
    6. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
    7. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
    8. Pharmacyclics, Inc. Prices Public Offering of Common Stock
    9. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
    10. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
    11. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/21/2015)... , April 21, 2015 The North ... at a CAGR of 7.9% from 2014 to 2019. ... ) command larger shares in the dermatology diagnostic ... to grow at the highest CAGR of 9.8% during ... devices market is driven by factors such as rising ...
    (Date:4/21/2015)... This report analyzes the worldwide markets for ... Equipment for Therapeutic Apheresis, and Equipment for Donor Apheresis. ... Plasmapheresis, Plateletpheresis, and Others. The report provides separate comprehensive ... Japan , Europe ... World. Annual estimates and forecasts are provided for the ...
    (Date:4/21/2015)... According to a new ... Cell, Blood, Gene Therapy), Product (Instruments, Services, Kits, ... Residual Contamination, Adventitious Agents) - Global Forecast to ... Testing Market was valued at $1,758.69 Million in ... a CAGR of 12.23% to reach $3,130.85 Million ...
    Breaking Medicine Technology:North American Dermatology Diagnostic Devices Market by Diagnostic Device, by Treatment Device, by Application - Forecast to 2019 2North American Dermatology Diagnostic Devices Market by Diagnostic Device, by Treatment Device, by Application - Forecast to 2019 3World Apheresis Equipment Industry 2World Apheresis Equipment Industry 3World Apheresis Equipment Industry 4World Apheresis Equipment Industry 5World Apheresis Equipment Industry 6World Apheresis Equipment Industry 7World Apheresis Equipment Industry 8World Apheresis Equipment Industry 9World Apheresis Equipment Industry 10World Apheresis Equipment Industry 11World Apheresis Equipment Industry 12World Apheresis Equipment Industry 13World Apheresis Equipment Industry 14World Apheresis Equipment Industry 15World Apheresis Equipment Industry 16World Apheresis Equipment Industry 17World Apheresis Equipment Industry 18World Apheresis Equipment Industry 19World Apheresis Equipment Industry 20World Apheresis Equipment Industry 21Biologics Safety Testing Market Worth $3,130.85 Million by 2019 2Biologics Safety Testing Market Worth $3,130.85 Million by 2019 3Biologics Safety Testing Market Worth $3,130.85 Million by 2019 4
    (Date:4/21/2015)... (PRWEB) April 21, 2015 The joint ... today it is opening its first freestanding emergency room ... Chandler, Arizona and will be licensed under Dignity Health ... Dignity Health and Adeptus Health joint venture. , Tim ... and Mercy Gilbert Medical Centers said the new facility ...
    (Date:4/21/2015)... NJ & New York, NY (PRWEB) April 21, ... leading global provider of advanced delivery technologies and ... products, today announced the launch of ADVASEPT™ Lock, ... safe and efficient delivery of injectable medications. Easily ... combining a safe, convenient and functional container closure ...
    (Date:4/21/2015)... Carinsurancehints.com has released a new blog ... impact on auto insurance prices . , ... prices. Clients should review their insurance options before deciding ... under several forms. Some of the popular policies provide ... compare online rates and find the best prices in ...
    (Date:4/21/2015)... PA (PRWEB) April 21, 2015 This ... & Related Skin Types, Inc.® (FIRST) will publish a ... The campaign will run throughout the month of May ... It Matters to Someone." The positioning was chosen ... this rare skin disorder and to help support our ...
    (Date:4/21/2015)... Carinsuranceshoppingsource.com has released a new blog ... insurance plans . , Comprehensive auto insurance is ... situations. The coverage limit can also be high and ... protect a car against fire damage, vandalism, theft and ... no longer difficult and it can help drivers find ...
    Breaking Medicine News(10 mins):Health News:Dignity Health and Adeptus Health to Open First Freestanding Emergency Room in Chandler, Arizona 2Health News:Dignity Health and Adeptus Health to Open First Freestanding Emergency Room in Chandler, Arizona 3Health News:Catalent Announces the Expansion of its Advanced, Aseptic, Glass-Free Injectable Platform with New ADVASEPT™ Lock Delivery Technology 2Health News:Heavily Circulated Roads Can increase Auto Insurance Costs 2Health News:May is Ichthyosis Awareness Month. Use Your Voice. 2Health News:Comprehensive Auto Insurance Is An Important But Complex Policy 2
    ... Kiadis Pharma,announced today that its lead product ATIR ... Food and Drug Administration (FDA) as a therapy ... Disease (GvHD),following allogeneic bone marrow transplantation. ATIR is ... enter clinical phase III,studies in 2008. "This ...
    ... to treat high blood pressure and enlargement of ... caused by post-traumatic stress disorder, Alzheimer,s disease, depression ... antipsychotic medication, appears to block the increase of ... Science University and Portland Veterans Affairs Medical Center ...
    ... Scientists at Cold Spring Harbor Laboratory (CSHL) have developed a ... genome that is more powerful and more economical than methods ... to be a boon to many kinds of research, including ... genes implicated in major diseases such as cancer and schizophrenia. ...
    ... CV Therapeutics,Inc. (Nasdaq: CVTX ) today reported financial ... the quarter ended September 30, 2007, the Company reported a ... to a net loss of,$62.7 million, or $1.23 per share, ... per share, for the prior quarter ended June 30, 2007. ...
    ... and 6 ... other cities, RALEIGH, N.C., ... on the impact of new CPR techniques, the,results of which support the ... the study authors in a,presentation at the AHA,s Scientific Sessions on November ...
    ... Concise reporting would ensure validity of patient safety findings, group ... to be used as hospital safety rating tools have been ... the guidelines could help do away with misleading safety comparisons ... reporting patient safety data on their Web sites. While this ...
    Cached Medicine News:Health News:FDA Grants Kiadis Pharma Lead Product ATIR Orphan Drug Designation 2Health News:FDA Grants Kiadis Pharma Lead Product ATIR Orphan Drug Designation 3Health News:Blood pressure drug curbs brain damage from PTSD 2Health News:CV Therapeutics Reports 2007 Third Quarter Financial Results 2Health News:CV Therapeutics Reports 2007 Third Quarter Financial Results 3Health News:CV Therapeutics Reports 2007 Third Quarter Financial Results 4Health News:CV Therapeutics Reports 2007 Third Quarter Financial Results 5Health News:CV Therapeutics Reports 2007 Third Quarter Financial Results 6Health News:CV Therapeutics Reports 2007 Third Quarter Financial Results 7Health News:CV Therapeutics Reports 2007 Third Quarter Financial Results 8Health News:Raleigh in National Study, Shows Survival to Hospital Discharge After Cardiac Arrest Doubles With Improved CPR and Impedance Threshold Device 2Health News:Raleigh in National Study, Shows Survival to Hospital Discharge After Cardiac Arrest Doubles With Improved CPR and Impedance Threshold Device 3
    For restriction digests, immuno-precipitations, enzyme assays, TLC spotting and others...
    ... to order tips. Each box contains 10,000 ... available in easy-to-open, re-sealable Bulk Packs of ... sealed with a tamper-proof strip which can ... Gilsons Diamond Tips. Bulk Packs are closed ...
    ... tips. Each box contains 1000 tips (5 bags ... tips (4 bags of 50 tips). Also available ... per pack. Bulk Packs are sealed with a ... quick access to Gilsons Diamond Tips. Bulk Packs ...
    Capillary section fits into a 0.3-mm well for accurate loading of sequencing gels - Ideal for use with CastAway System...
    Medicine Products: